Leading Companies Fueling Growth and Innovation in the Human Serum Albumin Market

The human serum albumin market is gaining significant traction as advancements in biotechnology and expanding healthcare needs drive demand worldwide. This market is poised for notable growth, fueled by innovations in production methods and increasing applications in medicine and research. Below is a detailed overview of the market size, key players, emerging trends, and segmentation that define this rapidly evolving sector.

Projected Expansion of the Human Serum Albumin Market by 2030
The human serum albumin market is anticipated to experience robust growth, reaching a value of $8.16 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 7.0%. Several factors are contributing to this rise, including advances in recombinant human serum albumin derived from yeast, bacterial, and plant sources. Additionally, there is growing demand for fatty acid-free formulations, expanding uses in drug delivery and nutritional enhancements, increased investments in research facilities, and greater procurement activities by hospitals and blood banks. Key trends during this period involve rising consumption of both plasma-derived and recombinant albumin, expanded application in volume expanders and drug delivery, wider adoption of lyophilized powders and injection forms, and a focused interest in specialty and fatty acid-free preparations.

Download a free sample of the human serum albumin market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Prominent Companies Leading the Human Serum Albumin Industry
A number of influential corporations currently shape the human serum albumin market landscape. These include Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring, Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, and Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

In a notable collaboration from June 2024, Proliant Health and Biologicals, based in the United States, partnered with Dyadic International Inc. to commercialize animal-free recombinant human serum albumin. This alliance aims to fast-track the availability and scalable production of non-animal-sourced albumin for use in diagnostics, cell culture, nutrition, and therapeutic fields. By combining Proliant's expertise in purified protein manufacturing and distribution with Dyadic's C1 microbial expression technology, this partnership seeks to enhance supply chain resilience, reduce dependence on plasma-derived materials, and meet stringent regulatory and customer demands for GMP-grade recombinant proteins. Dyadic International is recognized for its large-scale microbial production platforms, including the C1 system, which supports the manufacture of recombinant proteins and other biologics.

View the full human serum albumin market report:
https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Innovative Trends Shaping the Future of the Human Serum Albumin Market
Market leaders are increasingly focused on developing novel, animal-free recombinant excipients aimed at improving safety, scalability, and regulatory compliance in biomanufacturing. These excipients are biologically engineered substances produced through recombinant DNA technology without using animal or human-derived components, ensuring higher purity and safety in pharmaceutical applications. For instance, in April 2025, InVitri Inc., a US-based supplier of animal-free recombinant proteins and excipients, introduced Optibumin 25. This product is the first recombinant 25% human serum albumin specifically tailored for closed-system biomanufacturing. It is designed to optimize downstream processing, formulation, and cryopreservation workflows and is available in 100 mL single-use bags. With its chemically defined, animal-origin-free composition, Optibumin 25 offers consistent purity, lowers contamination risk, and meets GMP standards. It supports commercial-scale production and seamlessly integrates into applications such as viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Detailed Segmentation of the Global Human Serum Albumin Market
The human serum albumin market is categorized across several dimensions for a comprehensive understanding:
1) By Type of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin
2) By Formulation Type: Injection Solutions, Lyophilized Powder
3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies
4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents
5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Further subdivisions include:
- Recombinant Human Serum Albumin Types: Yeast-Based, Bacterial-Based, Plant-Based, Mammalian Cell-Based, and Insect Cell-Based
- Plasma-Derived Human Serum Albumin Types: 5% Solution, 20% Solution, 25% Solution, Lyophilized Albumin, and Fatty Acid-Free Albumin

These classifications illustrate the diversity of products and applications within the human serum albumin market, reflecting ongoing innovation and specialization tailored to diverse medical and research needs.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.